Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacrolimus versus dexamethasone for moderate to severe vernal keratoconjunctivitis in children in Ibadan
PACTR202405822048313Recruiting
- Sponsor
- adetola Ogunbiyi
- Start
- Jan 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Open-label trial of tacrolimus, dexamethasone, neomycin and polymyxin B in Vernal Keratoconjunctivitis (VKC), sponsored by adetola Ogunbiyi. Primary endpoints: Change in total composite score for VKC-related symptoms and signs at 4 weeks and Change in total composite score for VKC-related symptoms and signs at 8 weeks. Started Jan 2024; status: recruiting.
02
Drugs
tacrolimusdexamethasoneneomycinpolymyxin B
03
Conditions
Vernal Keratoconjunctivitis (VKC)
Beyond the preview
Go deeper on PACTR202405822048313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202405822048313.